Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
MagnetisMM-1
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
- NCT03269136 ↗
- Completed
- Pfizer
- Deep
We haven't built an HCP commentary report on MagnetisMM-1 (PF-06863135 + dexamethasone, PF-06863135 + lenalidomide and 1 more in Multiple Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MagnetisMM-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 18 | |
| YouTube | 10 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- MAGNETISMM-1 A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- PF-06863135 monotherapy IV or SC; PF-06863135 + dexamethasone; PF-06863135 + lenalidomide; PF-06863135 + pomalidomide
- Arms
- PF-06863135 · Experimental
- PF-06863135 + dexamethasone · Experimental
- PF-06863135 + lenalidomide · Experimental
- PF-06863135 + pomalidomide · Experimental
- Enrollment
- 101
- Primary outcomes
- Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version (v)4.03
- Part 2: Objective Response Rate (ORR) as Per International Myeloma Working Group (IMWG) Criteria
- Part 2: Duration of Response (DOR) as Per IMWG Criteria
- Sponsor
- Pfizer
- Start
- Nov 29, 2017
- Primary completion
- Jan 19, 2024
- Results posted
- Yes
- Registry record
- NCT03269136 · updated Mar 18, 2025
Publications
linked from the registry- Hibma JE, Irby D, Liu A, Elmeliegy M, King LE, Gifondorwa D, Jiang S, Poels KE, Soltantabar P, Lon HK, Shtylla B, Wang D, Williams JH, Nicholas T. Elranatamab Population Pharmacokinetics and Exposure-Response for Cytokine Release Syndrome in Patients with Relapsed or Refractory Multiple Myeloma. Clin Pharmacokinet. 2026 Aug;65(8):1173-1192. doi: 10.1007/s40262-026-01663-z. Epub 2026 Jun 13. PubMed 42287565
- Lon HK, Hibma J, Jiang S, Sullivan S, Vandendries E, Skoura A, Wang D, Elmeliegy M. Population Exposure-Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma. Target Oncol. 2025 Sep;20(5):803-819. doi: 10.1007/s11523-025-01168-y. Epub 2025 Aug 18. PubMed 40826257
- Elmeliegy M, Viqueira A, Vandendries E, Hickman A, Conte U, Irby D, Hibma J, Lon HK, Piscitelli J, Soltantabar P, Skoura A, Jiang S, Wang D. Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma. Target Oncol. 2025 Mar;20(2):349-359. doi: 10.1007/s11523-025-01134-8. Epub 2025 Feb 25. PubMed 40000533
- Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 Oct;29(10):2570-2576. doi: 10.1038/s41591-023-02589-w. Epub 2023 Oct 2. PubMed 37783970